click company/industri name report summari
price estim chang
strong result improv iphon trend solid growth busi area
maintain buy rais price target
anoth qualiti start one favorit small-cap pitcher reiter buy target
know vumer gi data half battl protect tecfidera ms franchis hold
down-the-middl quarter improv metric still hold pt
in-lin quarter buy pullback event acceler beyond target
disappoint lower guidanc ceo chang maintain buy lower price target
margin move next napervil review maintain buy target
bring strong diner growth improv deliveri econom maintain buy price target
surufatinib/savolitinib data expand elun access could help under-valued hcm share
visibl cloudi amid macro/trad turmoil guidanc street hold pt
book organ growth outlook reflect market strength buy pt
roll continu re-invest rather drive leverag buy pt
line expect anticip steadili improv trend reiter buy
summari publish mon-fri includ report publish sinc recent edit pleas refer individu report specif public price date
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect invest analyst person independ object view
design invest relev issuer discuss herein
research report uk produc canaccord genuiti limit authoris regul financi conduct author fca report
european issuer non-independ research market commun market abus regul fca conduct busi rule
canaccord genuiti australia limit australian affili global capit market group canaccord genuiti group inc cf tsx recommend
opinion express research report accur reflect analyst person independ object view design invest
import inform pleas see import disclosur begin page document
content growth variabl cost model still focu amid weaker auto sale macro environ
momentum pet enrol continu maintain buy price target
ratchet bar announc ceo chang lower pt
regist third consecut miss guid start year reiter sell pt
solid platform strategi start play buy pt
favor view expand relationship amazon aw maintain buy price target
make world lot smaller full-servic model first win reiter buy price target
summari publish mon-fri includ report publish sinc recent edit pleas refer individu report specif public price date
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect invest analyst person independ object view
design invest relev issuer discuss herein
research report uk produc canaccord genuiti limit authoris regul financi conduct author fca report
european issuer non-independ research market commun market abus regul fca conduct busi rule
canaccord genuiti australia limit australian affili global capit market group canaccord genuiti group inc cf tsx recommend
opinion express research report accur reflect analyst person independ object view design invest
back index
strong result improv iphon trend solid
growth busi area maintain buy rais
price target
invest recommend report strong result ep
consensu estim record june quarter revenu
slightli midpoint guidanc top line driven stronger
expect sale grew yoy wearabl yoy although
iphon result line expect declin yoy trend
china improv return growth constant currenc benefit govern
stimulu trade-in financ program grow engag across
ecosystem servic remain strong grow all-tim record quarter
achiev revenu surpass paid subscript tv
appl arcad launch fall appl card launch next month recent
launch news tv channel manag remain confid
achiev target doubl size busi guidanc
septemb quarter strong revenu mid-point gross
margin midpoint estim even account fx-
headwind includ guidanc manag return investor via share
repurchas dividend quarter consist state net cash-
neutral target believ ecosystem approach includ instal base
exce devic global lead record servic revenu expect
higher-margin servic revenu growth continu outpac total compani growth
given continu near-term soft sale trend latest line-up iphon
forecast year-over-year unit declin iphon sale anticip
unit growth base increas instal base drive higher iphon sale
includ anticip introduct iphon next fall base
result guidanc increas ep estim
reiter buy rate increas target
servic revenu growth continu impress driven product ecosystem servic
report anoth strong quarter grow all-tim record repres
yoy growth exclud one-tim lawsuit impact last year advers
fx headwind recent announc servic launch come month
includ card next month much-anticip tv fall
believ sustain double-digit servic revenu growth toward target
doubl revenu achiev subscrib
sever new oper system core app featur enhanc announc
june wwdc robust growth trend app store record perform
appl music appl cloud servic believ new servic launch
drive grow mix recur revenu product
increas iphon unit sale estim base revenu guidanc
estim adjust iphon unit sale estim
unit despit posit revis presid trump lift
china tariff hold iphon estim could prove aggress base on-going
trade tension china us survey indic consum
will wait iphon upgrad
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
biomed devic servic
anoth qualiti start one favorit small-
bottom line deliv solid in-lin print demonstr strong
underli fundament firm current core busi open appendag
manag continu see multipl tailwind respect franchis go
forward inde manag exud confid rais bottom end
guidanc project y/i sale growth vs enter
year print print reinforc belief
deliv solid double-digit growth next sever quarter via current
busi continu think best yet come note strong divers set
long-term growth driver includ potenti expand opportun recent
cryospher probe launch track ahead schedul open pain
manag field clinic data gener focus open new tam and/or
expand current one ramp gm gm expect long-term
margin profil expect reiter ultim mi af ablat arena
remain track submit fda late short see compel long-
term growth trajectori compani think stock follow suit
mi ultim repres atrc long-term growth driver expect mi
revenu trend vacil quarter quarter basi case
regard open busi see upsid setup concomit ablat
next sever quarter multipl factor least pain
manag opportun ahead firm could augment overal busi
growth potenti support hsd growth higher inde think recent
commenc ice-afib trial could act drive penetr open go
remain one favorit long-term stori small-cap med-tech given
upcom catalyst think acceler growth beyond well
firm larg still under-penetrated tam open/concomit af ablat
appendag manag latter think continu
grower next year least reiter buy rate target
open busi atrc us open busi continu produc solid consist
result franchis benefit top-lin initi
increment cryospher contribut regard firm recent launch
nerv block platform experienc posit feedback initi launch
drive expans atrc dedic clinic team ahead initi expect
stand today employ eight focus pain manag rep lack
suffici clinic support current repres biggest barrier
adopt long term manag view pain market sizeabl adjac
nich market opportun firm near term firm expect modest
acceler busi balanc build
dedic team robust expans begin
time-frame continu pg
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
know vumer gi data half battl
protect tecfidera ms franchis hold pt
defens win battl vumer war tecfidera continu
recal biib/alk report head-to-head gastrointestin toler data
vumer diroximel fumar vs tecfidera dimethyl fumar given
paid mileston see preliminari gi data see
surpris today report phase data show vumer significantli
better gi toler vs tecfidera multipl sclerosi ms tecfidera subject
sever patent challeng see review reiter view vumer
import cogs abil build defens franchis us around
tecfidera largest-sel product current maintain
perform hard switch patient alreadi tecfidera vumer
latter approv action date nevertheless believ case could
made start new patient vumer physician patient convinc
vumer profil rel benign vs tecfidera make case significantli
true gener enter tecfidera us key defens
brief look phase vumer gi toler data
biib/alk report patient treat vumer
report significantli fewer day gi symptom intens score
individu gastrointestin symptom impact scale igisi vs tecfidera
addit discontinu rate due gi advers event treatment
period lower vumer vs tecfidera biib/alk expect
present detail data phase trial futur
model unchang tecfidera gener specif valu vumer
model tecfidera sale revenu also continu
includ specif contribut vumer
us patent/exclus info tecfidera vumer quick dcf scenario
tecfidera new chemic entiti nce exclus expir current
three unexpir patent list orang book tecfidera expir date
vumer could
grant nce exclus expect patent expiri model assum
substitut gener arriv us prior patent expiri us tecfidera
gener entri assumpt move back dcf value-per-share
would go respect vs base case els equal
maintain hold construct valuat financi flexibl ignor pipelin
publish recent updat see remain construct
valuat also reflect pt unchang howev
wait glimps pipelin success and/or action later-stage-focus
busi develop remain difficult predict us get comfort
recommend stock sever pipeline-rel catalyst see tabl come
end mani indic challeng
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
enterpris softwar softwar servic
down-the-middl quarter improv metric still
hold pt
ceridian continu improv competit posit good featur innov
solid sale execut on-going age legaci hr manag system
stock bit tale citi headlin revenu growth margin
pedestrian suggest take closer look
impress dayforc growth continu run rang close
regress free-cash-flow headlin number say properli valu howev
growth compon ceridian becom bigger percentag total overal number
improv thing continu wrestl investor start
valu better metric seem like matter isnt
yet suspect upgrad hold could justifi quarter
differ expect ceridian alway good job explain
everi incom statement balanc sheet cash flow line item your good
model mani surpris inde put
take fact cant rememb middl fairway
quarter almost compani realiz trader want sort
epic disloc sinc focu compani execut long-run
nice solid quarter news wise canadian govern payrol avail
publicli earlier announc ceridian suffici confid
broad opportun creat new industri vertic reflect manag optim
segment
read-through public compani print broadli support
content chunk legaci firm fall bigger portion previou
valuat price target
rais price target everi softwar stock elev past peak
valuat reach new price target base ev/r multipl
appli cloud revenu estim plu approxim
roughli stock valu attribut discount profit declin bureau
busi analysi take consider approxim prospect
net debt assum fulli dilut share outstand altern target
impli ev/ebitda multipl appli estim also
ran long-term irr analys scenario yield price target depend
assumpt use
back index
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
biomed devic servic
in-lin quarter buy pullback event acceler
beyond target
bottom line would buyer pullback share compani
report in-lin y/i cc top-lin growth see myriad driver begin
kick second half year drive top-lin acceler
leverag model guidanc
came origin estim owe issu one
time natur larg work temporari suppli constraint
jotec vascular tissu graft think manag guidanc prove
conserv anticip growth driver jotec product launch proact xa trial
commenc come on-line sooner expect former headwind
larg attribut see necessari yet bullish stock ahead
ramp distributor network apac latam support consign
direct market test next-gen product line introduct new jotec product
europ expect benefit long-run
compani refresh jotec portfolio offer latter think ind
fda proact xa trial on-x use noac could drive market
awar around on-x acceler growth beyond approv
addit aforement driver continu believ cri product
pipelin perclot us bioglu china jotec product us
posit compani deliv acceler top-lin growth margin expans gross
 oper increas profit next year wit would look
pullback print add posit look
catalyt period company/stock reiter buy rate
acceler kick continu growth
quarter came in-lin expect growth jotec y/i cc
hinder steril issu caus compani lose product
outsid loss growth would cc basi jotec see
increas headwind relat apac latam distributor stock
consign direct market support next-gen product line test see
new product launch second half year appar
set compani deliv dd growth acceler firm
recent submit ce mark approv first two jotec product
manag expect approv product line addit firm
remain track receiv ce mark approv next-gen frozen eleph trunk
platform year end china submit regulatori approv
bioglu product set potenti approv market entri pend
chines regulatori timelin perclot us enrol recent complet
manag anticip pma fda earli eye approv
us market
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
disappoint lower guidanc ceo
chang maintain buy lower price target
report thesi predic belief share offer
valu compani track toward posit cash flow also recogn
challeng busi miss lower guidanc ceo
chang challeng previou thesi recommend maintain
current rate time recogn share like take signific
near-term hit increasingli becom appar castlight may benefit
review strateg altern better posit compani futur growth
take hit declin sequenti manag cite two
area declin compani expect direct sale ramp howev
despit solid pipelin convers meet intern target churn rear
head time castlight guidanc client base manag
note certain client decid default insur free offer specif
lost client ralli offer
lower guidanc castlight lower guidanc base lower direct sale
mention longer timelin launch client alreadi sign
lower sale custom engag partner previous
anticip revenu guidanc lower
non-gaap oper loss concern
lower direct sale longer timelin launch entir sure
compani rectifi issu short run posit side manag
indic pipelin solid hope convert deal
manag chang compani announc departur john doyl ceo
board director board appoint maev meara ceo
board ms meara compani variou role sinc
addit cfo nolan mangini appoint presid given difficulti
compani encount surpris see chang leadership
look get better insight ms meara strateg plan introduc
competit environ needless say benefit technolog area highli
competit ask manag perspect whether employ
payer may shift focu toward strateg value-add area
telehealth digit diabet offer manag state view relationship
area tailwind castlight note offer platform sale
requir buy-in stakehold within potenti client opinion
employ payer could focus easi win thu castlight may
disadvantag clearli need better understand dynam
valuat price target
lower pt base sale estim
discount cloud-bas peer share close
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
margin move next napervil review
maintain buy target
find well posit benefit converg popul
growth resourc volatil rapid industri across world compani
recur servic model drive high visibl even variabl macro environ
anoth quarter strong execut predict power platform
adjust oper margin y/i ep growth continu
favor long-term earn potenti despit valuat toward higher end
histor rang like much market favor long-term macro trend
proven execut better visibl lot room target market reiter
buy rate catalyst septemb investor day nalco headquart
outsid chicago
organ growth healthi across platform flatter expect
life scienc pest importantli
institut growth pick organ despit deliber exit low margin
activ healthcar also show solid improv tax-fre spin
upstream energi also stay track complet continu like
strategi includ like dividend base leverag newco
digit invest continu progress nice look deeper dive septemb
look drive continu competit advantag uniqu custom insight
enhanc sale effici etc compani erp roll-out us larg
complet continu like set-up also expect lag price
action drive improv margin keep price back-end
shown histor
guidanc get reiter sold organ growth segment adjust
ep still anticip y/i despit y/i fx headwind
target y/i inclus fx
headwind given solid balanc sheet net debt adjust ebitda
healthi gener convers expect expect
 remain key part strategi move forward perhap bolster futur
report revenue/adjust ep vs street
guidanc estim adjust reflect report
result updat assumpt follow
full detail
target equat price-to-earnings multipl
adjust ep estim acknowledg higher near-term multipl vs
high end histor averag stay confid long-term earn power
platform
back index
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
bring strong diner growth improv deliveri
result brought strong net diner addit revenu growth along
mostli in-lin profit despit revenu beat compani maintain
full-year revenu outlook expect lower ebitda profit
newer deliveri market gain order densiti help unit econom
expect deliv ebitda per order return level
acceler deliveri market expans heavier advertis spend
began weigh per-ord profit continu view power
two-sid marketplac strong grow select restaur
activ diner enhanc deliveri capabl maintain buy rate given
reason valuat long-term growth outlook
diner growth acceler perk way diner growth
acceler y/i vs compani ad net
new diner diner growth driven continu effect
market campaign grow restaur select restaur platform
vs recent expans new market pilot
new perk featur sever market aggreg diner person
discount incent loyalti reward one place promot
restaur fund control adjust restaur real time
improv engag order frequenc integr loyalti program
perk yet anoth benefit levelup acquisit differenti
offer manag note already-budget nation market
campaign support perk come fall
address seri sharp media articl busi practic
reaffirm action surround demand gener phone order
white label websit cooper restaur partner
explicitli laid restaur agreement addit order gener
channel combin repres low-single-digit total order manag
note none issu measur impact busi
mix guidanc compani introduc mix guidanc
expect revenu in-lin prior estim
consensu expect adj ebitda come
estim consensu encouragingli ebitda per
order expect continu recoveri move
manag updat full-year outlook revenu unchang
midpoint prior guidanc adj ebitda vs prior guid
valuat price target remain unchang base adj
ebitda estim support dcf valuat
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
surufatinib/savolitinib data expand elun access
surufatinib non-pancreat net data come esmo
expect see granular detail sanet-p studi surufatinib neuroendocrin
tumor net esmo could support meaning us commerci
opportun futur importantli sanet-p studi china halt one year
earli due strong efficaci base progress free surviv net patient
live mani year progress slowli often treat mani differ
therapi see multipl opportun surufatinib potenti shine
phase chines data readout esmo potenti nda submiss
chines regulatori bodi potenti approv us fda end
phase ii meet pancreat net
hcm work expand access fruquintinib elun china
hcm look expand access elun china get product onto
provinci nation reimburs drug list critic step hcm present
shanghai provinci reimburs drug list give fruquintinib access
china largest citi popul compani continu work obtain nation
reimburs statu china even limit patient access program
non-reimburs initi payment system hcm partner estim
gener fruquintinib sale expect sale move higher
shanghai reimburs statu began june final nation
reimburs statu decis avail would trigger automat
distribut china hospit pharmaci fruquintinib ad
savolitinib combin tagrisso promis
phase savannah interim data announc savolitinib
tagrisso combin previous shown promis efficaci met iressa/tarceva/
tagrisso failur nsclc patient median durat respons month iressa/
tarceva failur patient overal respons rate median durat
respons month tagrisso failur patient overal respons
rate led initi savannah phase global single-arm studi
slate complet current manag partnership astra
zeneca explor novel dose regimen reduc advers event
give patient tagrisso mg daili savolitinib mg depend
patient weight
maintain buy rate price target base view savannah
studi could show high respons rate may lead effici approv
pathway also recent posit data surufatinib neuroendocrin tumor
signific posit could hold addit upsid replic us studi
close monitor data updat tatton studi assess bar
success savannah trial believ hcm share under-valued current
level would buyer
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
visibl cloudi amid macro/trad turmoil
guidanc street hold pt
report essenti in-lin yet comment trend worsen
materi follow last updat provid earn call
compani post revenu ep comparison
expect respect
compani rel upbeat potenti inflect
higher april current view relay quit bit pessimist near term
china demand sluggish macro on-going us-china trade conflict cite
encouragingli near-term margin like compress given
heighten competit environ within lower power laser market
quit adam high power categori ultra-high power categori
greater remain limit competit
recogn risk miss bottom trade stubbornli wait
visibl demand improv becom construct share
look forward compani present global growth
confer next week contact canaccord genuiti sale repres
maintain hold rate lower price target reflect
increas uncertainti base ep estim
back index
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
aerospac defens
strength buy pt
report ep compar estim
consensu quarter highlight record book
adjust ebitda margin organ revenu growth
exclud revenu time impact
compani announc acquisit american panel guid
ep ebitda ahead current expect maintain buy rate
increas price target
compani announc acquisit american panel corp apc
expect close fiscal acquisit compani
avion busi combin ce rtl geco pay
gross basi impli next twelve-month ebitda apc note
apc guidanc apc well posit sever notabl platform
ground vehicl expect compet
larger avion opportun compani view avion push well posit
benefit suppli chain de-lay see market
compani highlight new program start opportun strong
compani guid softer margin due higher capital-expenditure
invest intern capabl build-out wrap current plan
also compani expect see revenu contribut
margin volum growth howev believ strong book
across point strong new busi environ elev
outlook view posit consid contribut organ growth
initi guidanc call revenu growth organ
basic flat margin expect consist prior guidanc
conservat bake outlook howev conserv ebitda margin
guidanc one area investor pushback also see work capit
improv impli guidanc strong perform one
opportun manag highlight demand custom microelectron
compani meet phoenix facil compani posit
lead market commerci special silicon product defens
applic see strong demand
updat ep estim
respect believ investor sentiment continu driven larg organ
top-lin growth initi outlook encourag confid
margin opportun improv organ growth invest opportun
agre invest capit current opportun strong
market environ best use capit resourc
maintain buy rate increas price target
price target base blend ep multipl ebitda multipl
appli estim consid potenti double-digit organ growth
increment acquisit margin expans strong market backdrop believ
sentiment stock remain posit
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
biomed devic servic
back index
roll continu re-invest rather
bottom line nuvas undoubtedli strong compani outperform
cg/street expect top bottom line second quarter
row share momentum pick year ytd though note
earli may high continu believ remain one
attract name med-tech robust new product flow stable/improv us spine
market continu ou share take clear lt margin expans road map
top line guidanc unchang remain larg conserv taken face
valu posit compani anoth year invest howev start
see evid ampl opportun upsid current estim particularli
season strong second half year still work
regain investor trust choppi suggest investor take anoth hard
look current valu consensu revs/ebitda/ep
ahead expect acceler commerci momentum
sale result report rev y/i xfx
cg/street us spine rev y/i well
estim though us surgic support slightli y/i vs
cg estim revenu growth well
expect manag note strong result emea
region off-set continu headwind apac latin american region
particularli japan australia/new zealand surgic support impact
biolog y/i in-lin manag expect although note
manag continu guid segment flat modest growth end
year mean start see growth return
oper continu show execut margin keep
investor interest move forward said guidanc continu point toward
reinvest busi rather drive oper leverag specif
improv y/i compani continu benefit effici initi
new manufactur facil well improv billing/collect servic
busi non-gaap om flat y/i improv q/q driven
cog sm effici slightli off-set plan invest
manag note om came intern expect full year guidanc
adjust net net continu view lt
margin stori posit top-lin growth continu trend favor
dilig suggest see opportun extend period upsid bia
ep leverag beyond
new product flow support near-term growth manag note us launch
puls on-going alpha/beta trial select ou market current underway
manag confirm addit detail share investor day next
week full unveil nass septemb said also highlight broader
pipelin implant/procedur product equal robust note dd growth
xlif alif franchis driven continu adopt singl posit later
system continu view new product addit combin puls
opportun compel valu driver move
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
internet thing
line expect anticip steadili
improv trend reiter buy pt
invest recommend sequan report revenu line
stronger expect product revenu grew sequenti
off-set softer revenu due lumpi strateg deal non-ifr gross
margin estim reflect higher mix modul
versu chipset declin mix revenu manag highlight
progress measur improv cash posit includ potenti expand
scope previous mention strateg deal well new discuss
potenti deal manag highlight backstop exist
long-stand sharehold execut compani option need
despit manag continu expect sequenti growth continu
remaind driven increas iot revenu continu estim
revenu lower given weak start believ broadband
sale stabil could return growth global carrier launch
network includ japan australia south korea europ believ
sequan well posit build leadership posit anticip iot-rel
revenu ramp beyond anticip grow
along potenti becom larger-than-anticip market
combin expect sale start ramp
beyond anticip iot sale drive sequan growth sequenti throughout
maintain belief sequan uniqu posit strong long-
term iot-rel sale growth believ sequan benefit lead carrier
transit global carrier launch nb-
iot network fact sequan doubl pipelin sinc last year
custom lead oem includ gemalto sever lead odm direct-end
custom repres futur revenu given posit momentum
broadband iot off-set lumpi vertic market model remain basic
unchang reiter buy rate price target
indic expect cat-m/nb project drive expect ramp iot
despit market slower develop delay rollout manag highlight
recent win product new design win nearly-secur win support
futur iot revenu grow last quarter manag also
discuss continu expand pipelin futur opportun across tracker
smart citi applic highlight europ momentum expect follow us
japan iot ramp new monarch us nb devic launch
year believ sequan iot revenu materi ramp exit beyond
balanc sheet remain focu cash-flow break-even manag highlight
potenti scope expans multimillion-dollar deal mention last quarter
strateg custom help drive iot market share expans invest would
equiti compon would up-front cash compon manag
also highlight addit potenti strateg discuss includ
new quarter hope secur least one deal
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
content growth variabl cost model still focu
st report essenti in-lin result yet comment trend appear
worsen lower full-year expect rel view provid
compani post revenu ep comparison
expect respect
compani expect result revenu adjust ep
approxim comparison prior view
reduc guidanc disappoint believ transform
variabl cost model help st maintain profit anticip
cost lever avail current weak intensifi
compani move toward ev market new partnership
lithium balanc help posit compani burgeon space
expand opportun electrif
maintain buy rate price target base dcf
back index
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
momentum pet enrol continu maintain
trupanion result brought continu consist subscript busi
number pet enrol grew y/i stronger dynam
busi white label solut allow compani captur
increment growth categori expans lower gross margin appear
relat faster expect softwar roll-out short-term mismatch
claim process insur rate expect correct time
regulatori consider appear control compani remain support
licens requir categori evolv continu view
steadi long-term grower larg address market maintain buy rate
momentum pet enrol continu subscript enrol pet grew y/i
net new pet ad mark highest net add sinc
arpp increas y/i expand third quarter row
manag expect continu howev gross margin came
lower expect due part faster-than-expect adopt trupanion
softwar busi includ employe benefit program
insur veteran servic dog impress revenu grow
y/i manag believ categori expand number brand
increas meaning similar happen uk pet insur market
matur think compani behind mani brand
diversifi pet acquisit effort trupanion ad dedic account
manag contact hospit territori partner visit goal
increas softwar adopt manag expect becom core part
market budget irr improv dtc market effort becom part
core spend certain matur market remain mostli growth bucket
manag note see dtc effort lead gener instead
convers tool initi increas lead convers retent rate
improv up-front educ encourag still earli stage
regulatori updat manag provid brief regulatori updat note
noth settlement washington oic expect settlement
california dept insur relat licens call-cent personnel materi
chang way busi compani adequ reserv
potenti fine expect materi financi impact result believ
would net posit busi licens becam requir
guidanc rais visibl improv revenu guidanc impli
consist y/i growth mid-point revenu guidanc
increas time mostli base improv visibl
busi segment manag reiter expect arpp growth aoi
y/i growth allow pac spend rang
valuat maintain price target base
revenu estim pt also support dcf valuat
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
diagnost tool
back index
ratchet bar announc ceo
chang lower pt reiter buy
share indic hour compani deliv modest
miss slash revenu guid instrument placement
cite one-quart push-out length custom valid one-quart
push-out research revenu due time also announc longtim ceo john
mcdonough appoint execut chairman step role
ceo conduct search new ceo disappoint
magnitud guid express concern guid
revenu fall seem like difficult bar good news
bacteria panel sale grew q/q demonstr momentum build
import new test reiter buy lower pt
use multipl revenu discount back three year
bit light rev miss hit low
end guid product rev y/i miss
place instrument hit low end guid sell
nine capit forecast three though one sold us
slash guid slash revenu guid
midpoint prior guid far prior street-low estim
street guid assum product rev
research rev assum new research contract
announc later year confid secur contract believ
time issu lower placement guid instrument
assum placement expect opex
come quarter plan reduc cash burn
end cash
announc ceo chang announc longtim ceo john mcdonough
becom execut chairman step ceo role conduct
search replac declin provid timet hire new ceo
light guid guid product rev prior
mainli reflect longer custom valid period observ
month vs origin target month
chang sale forc said turn bottom third sale
forc struggl place instrument intend replac rep begin
target infecti diseas pharmaci specialist member hospit stewardship
committe also plan hire direct rep dedic iarg idn think new
ceo may elect increas size sale forc acceler demand
catalyst may publish result panel pivot
fda clinic trial annal intern medicin may lead greater doctor
awar test adopt recent distribut agreement five ou
distribut partner expect on-going custom success stori lead greater
uptak expect ce-mark new panel launch ruo end
continu enrol lyme diseas test new ceo hire
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
diagnost tool
back index
regist third consecut miss guid
start year reiter sell pt
valu eye behold share increas today puzzl us
sinc deliv top line quarterli miss reduct revenu
guidanc think may record still juli
call today manag affirm turnaround take time believ
least two year away best worrisom fundament
busi continu deterior given pressur competit price margin
need spend need migrat anoth system platform overhang
fda magellan reiter sell rate pt
third straight miss rev y/i miss our/street prior
driven broad-bas weak diagnost declin vs driven
declin molecular dx declin gastrointestin rev volum
declin diff declin pylori rev due price eros life scienc
rev declin due soft america declin molecular
reagent miss meridian manufactur ep
beat base lower invest lower commiss paid sale rep miss
number adj ep beat
third straight guid expect rev declin y/i
y/i expect high-single-digit declin diagnost rev mid-
high-single-digit declin low-single-digit growth life scienc low mid-
single-digit continu expect price pressur pylori rise competit
molecular diagnost uncertain demand life scienc china
diagnost unlik return growth least expect
return growth diagnost least model y/i
expect on-going price pressur pylori volum declin diff test
look launch new test genepoc revogen
overlap alethia system built new product
develop team focu gi pediatr poc test
strateg shift curb share loss similar strategi
meridian like genepoc abil multiplex target launch new mini-
panel plan advanc develop gi respiratori panel initi
perhap advanc hai std panel road take time money
indic us neither gi respiratori panel initi clinic trial
thu see impact realist view
look swap low-util alethia instal base believ clear
path convert alethia formerli illumigen molecular box
instal custom site look convert custom basi higher
throughput ease-of-us new futur test menu
tick ep guid sometim one bright spot miss top line beat
bottom line pay commiss salesforc given bottom line
beat rais adj ep guid declin
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
enterpris softwar softwar servic
solid platform strategi start play
buy pt
post anoth solid quarter highlight rpo growth revenu
growth ahead consensu oper margin improv bp
y-o-i continu believ product bundl suit newli introduc
duet sell support remov friction multi-product sale cycl drive
strateg custom convers pursu strategi up-market
think long-term also encourag qualit commentari around earli
engag sunshin relat ecosystem build believ traction
broader custom experi platform import sustain
multi-year run growth next catalyst front addit color
plan monet expect receiv zendesk relat
event march earlier softwar sector qualiti asset
quit expens continu see rel valu believ firm
commit deliv balanc high growth consist margin expans
compel increment buyer time buy rate unchang
differ view guidanc year adjust
midpoint primarili order incorpor expens relat
smooch acquisit refin compani cash flow forecast
methodolog rpo year-over-year far ahead unguid
estim led compani focu long-term deal also help larger
deal size compani continu advanc upmarket enterpris custom
deriv read through result give us confid slow
custom experience/sal technolog space view bode well
low-end salesforc addit believ on-going
mid-market enterpris servic cloud upgrad tailwind firm like
provid underli infrastructur migrat contact center cloud
bullish item success execut move market reflect
rpo growth percentag custom
agent advanc year ago manag compel
aspir smooch acquir may year smooch messag
capabl posit center platform june
introduc first combin offer sale custom servic call duet
provid access sell support singl paid custom account
recal introduc sell last user confer novemb
along sunshin explor compani receiv good initi feedback
duet plan demonstr famili product sunshin
platform come togeth relat confer march miami
bearish item besid guide-down mention earlier growth emea
apac respect quit meet expect due
sub-optimal execut certain pocket market australia uk
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
favor view expand relationship
favor view today amazon web servic aw
aw prefer cloud partner bring innov healthcar market
confer call ask compani potenti transit cloud
provid aw manag state review capit structur
busi move cloud provid could contempl today
announc provid framework occur time
think transit aw suspect first step toward transit
could includ offer healtheint alreadi cloud base careawar
app layer millennium second given communitywork alreadi saas-bas
thu less like requir heavy-lift move data center aw
offer could next transit addit saa offer could
also transit final larger health system millennium offer would like
last transit key move larger millennium base would effort
modern current offer mean uplift client singl version
effort manag state current complet
modern also like focu improv user experi
transit aw take time achiev first sever step would free space
current data center thu potenti requir lower capit requir
long term believ agreement posit assist
drive acceler revenu growth introduct next gener product
servic incorpor artifici intellig ai machin learn ml
help drive sustain margin expans transit base full saa
regard new product innov potenti revenu acceler remain
optimist combin amazon aw signific technolog innov
experi healthcar domain experi formid believ
partnership could speed develop time-to-market new offer
look gain addit insight revenu opportun strateg collabor
notabl oper margin target
predic shift aw would also highlight compani re-affirmed
express confid attain target last week confer call
although margin target conting transit aw believ
move long-term posit margin provid path
reduc capital-expenditure on-going expens relat data center improv
implement effici timelin
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
biomed devic servic
make world lot smaller full-servic model
bottom line earlier today announc first two success lung transplant
use organ system oc lung platform part uniqu full-servic
model pilot program donor lung retriev hawaii initi declin
transplant due time and/or distanc limit success implant
patient north carolina arizona hour donor retriev
respect transplant recipi alreadi discharg hospit
think mileston signific exemplifi oc uniqu abil
effect keep organ aliv assess transit amelior time
distanc barrier heretofor preclud broader organ share long
term think model uniqu abil materi increas number
organ util transplant possess myriad catalyst market
indic expans think promulg ramp adoption/util
oc long term said think full-servic model could ultim
game-chang organ transplant
recent initi coverag buy rate see note think
firm via oc technolog well posit chang paradigm
field organ transplant long term lung heart liver possibl
kidney oc system directli address major limit cold storag
current soc organ preserv estim opportun oc calcul
multibillion-dollar target address market think oc
profound effect supply/demand imbal exist today
potenti long-term game changer long term think next compel
paradigm-chang driver business/stock could broad adopt
firm full-servic model present kick pilot program hawaii
upcom puerto rico think model could game changer
organ transplant field gener specif
full-servic model logist firm current hawaii forthcom puerto
rico pilot program act full-servic organ procur team provid
transplant support institut personnel act clear hous
organ take initi respons organ donor transport organ
oc deliv directli recipi transplant hospit oc abl
assess optim organ throughout process
address key limit cost associ organ procur part
potenti futur full-servic model could becom major player
way organ procur manag donor recipi today model
could allevi much transplant center resourc constraint logist
strain remov travel associ workflow interrupt transplant
center possibl increas total number transplant center perform
save healthcar system money
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
learn fli year ago flight instructor gave talk
get there- refer decid fli get somewher vs simpli
wait weather situat fli tire rush
although could affect pilot explain happen
experi figur handl current level overbought
volatil like decid fli weather uncertain pilot rush
probabl noth happen worth risk mayb fed announc
ep releas econom data discount key tactic indic continu
suggest wait weather bit
four key indic still suggest pullback close proxim record-high level
major market indic accompani littl progress either direct kept
key tactic indic level point temporari correct similar last
particip wane percentag index compon
move averag current respect figur
appear peak suggest market alreadi correct intern
volatil volatil index vix recent drop low
stood prior april correct figur
extrem overbought trusti stochast indic turn lower
extrem overbought level scale figur level
overbought bull market isnt neg thing sign time
increas optim percentag investor intellig bullish newslett writer
remain fairli complac level figur
extrem level bullish point bit complac middl
summari believ remain midst near-term
consolidation/correct period continu overbought territori
correct intern said still-posit core fundament thesi current
valuat level intermediate-term tactic backdrop suggest weak
prove limit temporari provid attract entri point move
toward target simpli believ tactic indic suggest
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
